Pioneering cancer survivorship care in Latin America: Early results from the OC sobre VIVER program in Brazil.

L Luciana Landeiro (Oncoclínicas&Co, Salvador, Brazil) T Thaiana Aragão Santana (Oncoclínicas&Co, Aracaju, Sergipe, Brazil) M Mônica de Azevedo Kalile Kalile (Oncoclinicas&Co, Salvador, Brazil) C Carla Pavei (Oncoclínicas&Co, Sao Paulo, Brazil) E Elisa Mascarenhas (Oncoclínicas&Co, Brasila, Brazil) M Maria Cecilia Borges Bittencourt (Oncoclínicas&Co, Sao Paulo, Brazil) F Fernanda Oliveira (Department of Medicine, Federal University of Sao Paulo) T Thais de Melo Passarini (Oncoclínicas&Co, Minas Gerais, Brazil) D Denise Strassburger Nunes (Oncoclínicas&Co, Belo Horizonte, Brazil) C Cristiane Decat Bergerot (Oncoclinicas&Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil) F Flavia Santos Dumont Sorice (Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil) B Bruno Favato Neto (Oncoclínicas&Co, Sao Paulo, Brazil) M Maria Helena Cruz Rangel Silva (Oncoclínicas&Co, Belo Horizonte, Brazil) H Helaine Pantoja (Oncoclínicas&Co, Rio de Janeiro, Brazil) C Carolina Perini (Oncoclínicas&Co, Curitiba, Brazil) M Mariana Laloni (Oncoclinicas&Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil) R Rafael Brant Costa (Oncoclínicas&Co, Belo Horizonte, Brazil)

Abstract

1640 Background: Cancer survivorship poses a growing challenge, especially in low- and middle-income settings. The OC SobreVIVER program, launched in October, 2020 by the Oncoclínicas Group, addresses survivorship care gaps by providing structured, multidisciplinary care. Initially piloted for breast cancer survivors in two Brazilian units, the program expanded in 2023 to include colorectal and prostate cancer survivors across eight states. This study presents preliminary data. Methods: This descriptive, observational study assessed the OC SobreVIVER program’s impact on survivorship care. Multidisciplinary consultations involving oncologists, nurses, psychologists, and nutritionists addressed late toxicities, recurrence risk, and quality of life, following international survivorship guidelines. Telehealth and digital tools improved accessibility. Data from July, 2023 to December, 2024 included clinical characteristics, program metrics, and patient-reported satisfaction via EORTC PATSAT 33 and Net Promoter Score (NPS). Descriptive statistics summarized key outcomes. Results: From July 2023 to December 2024, the program supported 577 survivors (518 breast, 47 colorectal, 12 prostate) across 11 practices in eight states, with 490 initial consultations, 91 follow-ups, and over 20 support groups conducted.Virtual consultations were available to all patients, enhancing accessibility for underserved regions. Patient-reported satisfaction was high, with 95% of respondents classified as Promoters (scores 9–10) in the NPS, demonstrating strong program loyalty. Based on EORTC PATSAT 33 evaluations, over 80% of respondents rated their medical care experience in the highest satisfaction range (41–50), and over 80% rated their nursing care experience in the highest category (29–35). Minimal dissatisfaction was reported, with less than 2% of responses falling into the lowest satisfaction ranges (< 20 for medical care and < 14 for nursing care). Conclusions: The OC SobreVIVER program demonstrates the feasibility of a structured, multidisciplinary survivorship model in a private network across Brazil. Preliminary data highlight its effectiveness in addressing complex survivorship needs, enhancing accessibility through telehealth, and maintaining high satisfaction.This integrated, patient-centric approach ensures continuity of care across physical, social, psychological, spiritual, and nutritional dimensions, fostering a more comprehensive and holistic survivorship experience.

Article Details

Volume / Issue Vol. 43, Issue 16_suppl
Published June 01, 2025
Pages 1640-1640
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (17)

L

Luciana Landeiro

Oncoclínicas&Co, Salvador, Brazil

T

Thaiana Aragão Santana

Oncoclínicas&Co, Aracaju, Sergipe, Brazil

M

Mônica de Azevedo Kalile Kalile

Oncoclinicas&Co, Salvador, Brazil

C

Carla Pavei

Oncoclínicas&Co, Sao Paulo, Brazil

E

Elisa Mascarenhas

Oncoclínicas&Co, Brasila, Brazil

M

Maria Cecilia Borges Bittencourt

Oncoclínicas&Co, Sao Paulo, Brazil

F

Fernanda Oliveira

Department of Medicine, Federal University of Sao Paulo

T

Thais de Melo Passarini

Oncoclínicas&Co, Minas Gerais, Brazil

D

Denise Strassburger Nunes

Oncoclínicas&Co, Belo Horizonte, Brazil

C

Cristiane Decat Bergerot

Oncoclinicas&Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil

F

Flavia Santos Dumont Sorice

Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil

B

Bruno Favato Neto

Oncoclínicas&Co, Sao Paulo, Brazil

M

Maria Helena Cruz Rangel Silva

Oncoclínicas&Co, Belo Horizonte, Brazil

H

Helaine Pantoja

Oncoclínicas&Co, Rio de Janeiro, Brazil

C

Carolina Perini

Oncoclínicas&Co, Curitiba, Brazil

M

Mariana Laloni

Oncoclinicas&Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil

R

Rafael Brant Costa

Oncoclínicas&Co, Belo Horizonte, Brazil